LEADER 03922nam  22005895  450 
001 9910734856003321
005 20251008143544.0
010   $a3-031-28046-6
024 7 $a10.1007/978-3-031-28046-7
035   $a(MiAaPQ)EBC30612947
035   $a(Au-PeEL)EBL30612947
035   $a(DE-He213)978-3-031-28046-7
035   $a(PPN)272271136
035   $a(CKB)27286052100041
035   $a(EXLCZ)9927286052100041
100   $a20230629d2023      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 14$aThe Bethesda System for Reporting Thyroid Cytopathology $eDefinitions, Criteria, and Explanatory Notes /$fedited by Syed Z. Ali, Paul A. VanderLaan
205   $a3rd ed. 2023.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2023.
215   $a1 online resource (292 pages)
311 08$aPrint version: Ali, Syed Z. The Bethesda System for Reporting Thyroid Cytopathology Cham : Springer International Publishing AG,c2023 9783031280450 
320   $aIncludes bibliographical references and index.
327   $aOverview of Diagnostic Terminology and Reporting -- Nondiagnostic/Unsatisfactory -- Benign -- Atypia of Undetermined Significance -- Follicular Neoplasm -- Follicular Neoplasm, Hürthle Cell Type -- Suspicious for Malignancy -- Papillary Thyroid Carcinoma and Variants -- Medullary Thyroid Carcinoma -- Poorly Differentiated Thyroid Carcinoma -- Undifferentiated (Anaplastic) Carcinoma and Squamous Cell Carcinoma of the Thyroid -- Metastatic Tumors, Lymphomas, and Miscellaneous Lesions -- Clinical Perspectives and Imaging Studies -- Molecular and Other Ancillary Tests.
330   $a The previous edition of The Bethesda System for Reporting Thyroid Cytopathology provided important updates and advances in the practice of thyroid cytopathology. It was inspired by new developments in the field of thyroid cytopathology since the publication of the first edition in 2010. These included revised clinical guidelines for the management of patients with thyroid nodules, the introduction of molecular testing as an adjunct to cytopathologic examination, and the reclassification of the non-invasive follicular variant of papillary thyroid carcinoma as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). This new third edition provides updates to the current reporting terminology and diagnostic criteria, including new information on ancillary molecular testing, as well as imaging findings and clinical management. This book provides a more unified approach to diagnosing and reporting thyroid FNA interpretations.It simplifies the reporting structure by settling on just one name for each of the six categories and aligning terminology with the most recent classification of thyroid tumors by the World Health Organization. Written by experts in the field, The Bethesda System for Reporting Thyroid Cytopathology, Third Edition aims to inspire advances in thyroid cytopathologic diagnosis and the betterment of patients with thyroid nodular disease. It serves as a reference guide not just for pathologists, but also endocrinologists, surgeons, and radiologists.
606   $aPathology
606   $aInternal medicine
606   $aSurgery
606   $aPathology
606   $aInternal Medicine
606   $aSurgery
615  0$aPathology.
615  0$aInternal medicine.
615  0$aSurgery.
615 14$aPathology.
615 24$aInternal Medicine.
615 24$aSurgery.
676   $a621
676   $a616.44
702   $aAli$b Syed Z.
702   $aVanderLaan$b Paul A.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910734856003321
996   $aThe Bethesda System for Reporting Thyroid Cytopathology$93553861
997   $aUNINA